Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A day in the life of patient advocate, Emily Ullrich

Emily Ullrich is a former professor of Communication Arts and Founder of Nairobi Film Institute, a nonprofit organization she created and where she taught filmmaking to college aged youth in Nairobi, Kenya for free. She was sick for many years before she was diagnosed with Interstitial Cystitis, Endometriosis, and Complex Regional Pain Syndrome in 2015, and Ehlers Danlos Syndrome in 2019, and has had to adapt her lifestyle according to her medical issues.

According to a study published in 2019, roughly 70% of patients diagnosed with Ehlers Danlos are women:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858200/#:~:text=We%20found%206021%20individuals%20(men,a%20practice%20of%205000%20patients.

Diagnostic criteria for the disease can be found at the following link:

https://www.ehlers-danlos.com/wp-content/uploads/2017/05/hEDS-Dx-Criteria-checklist-1.pdf

#interstitial #cystitis #endometriosis #CRPS #Ehlers #Danlos

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!